Developing new pharmacological chaperones for the treatment of rare metabolic diseases.
Atlas Molecular Pharma has raised €3.0M across 1 funding round from 3 investors, most recently a round in Feb 2022. Based in Derio, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-02-01 | Other |
| €3.0M |
| CDTI,Ezten Venture Capital Fund,Inveready |
| View deal → |
